Factor hitting hard with the GLP-1 included campaign

Physician always trying to learn, passionate about healthspan and precision medicine.

omarsaleem.xyz

United States spends the most on GLP-1 advertising. This is primarily because direct-to-consumer pharmaceutical advertising (DTCA) is only legal in the US and New Zealand, and the US market is by far the largest and most active in this space. In 2023, GLP-1 drug advertising spend in the US topped $1 billion, with the majority of this spending focused on diabetes and weight loss drugs such as Ozempic, Wegovy, and Mounjaro.
Major pharmaceutical companies like Novo Nordisk and Eli Lilly are the leading spenders, with TV advertising alone for GLP-1 drugs in the US exceeding $400 million in the past year. 

🙈🙈🙈💰💰💰💰it’s a cosmetic product for business not services real humanity and helping people. 

All about business